A3 cont'd configuration.

4. (cancelled)

5. (cancelled)

6. (Amended) A method for synthesis of the stereochemically active compounds according to claim 1, being of the R- or S-configuration, comprising the conversion of the corresponding stereochemical isomers of ketotifen into their 1-(2,2,2,-trichloro ethoxycarbonyl) nor-intermediates, followed by Cd/Pb-catalyzed cleavage to the products.

A4

7. (Amended) A method for preventing or treating a disease selected from the group consisting of respiratory disorders, allergic disorders, dermal disorders, gastrointestinal disorders and ocular disorders, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound selected from the group consisting of racemic norketotifen and stereochemical isomers thereof, the S-isomer of ketotifen, or pharmaceutically acceptable salts or solvates thereof, while avoiding the dose-limiting sedative side effects of ketotifen.

16. (cancelled)

17. (cancelled)

20. (Amended) A method of administering to a mammal in need thereof a composition, said composition comprising a therapeutically active amount of racemic or an optically active isomer of norketotifen, or the S-isomer of ketotifen, or a pharmaceutically acceptable salt or solvate thereof together with one or more drugs of the class consisting of adrenergic antagonists, analgesics, antihypertensive agents, calcium antagonists, antihistamines, anticholinergic agents, antibacterial agents, antiviral agents, antiinflammatory agents, bronchodilators, decongestants, steroids, leucotriene antagonists, lipoxygenase inhibitors, local anesthetics, vasoconstrictors, vasodilators, cough suppressants, and expectorants.

A5